KALA
KALA BIO, Inc. NASDAQ Listed Jul 20, 2017$0.08
Mkt Cap $1.8M
52w Low $0.08
0.0% of range
52w High $20.60
50d MA $0.22
200d MA $3.21
P/E (TTM)
-0.0x
EV/EBITDA
0.1x
P/B
0.1x
Debt/Equity
0.0x
ROE
-385.6%
P/FCF
-0.1x
RSI (14)
—
ATR (14)
—
Beta
-1.99
50d MA
$0.22
200d MA
$3.21
Avg Volume
7.5M
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
1167 Massachusetts Avenue · Arlington, MA 02476 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15, 2026 | AMC | -0.17 | 0.86 | +605.9% | 0.20 | -1.2% | -3.9% | +4.1% | +0.6% | -7.4% | -4.6% | — |
| Nov 19, 2025 | AMC | -1.01 | -1.07 | -5.9% | 0.63 | +2.7% | +2.5% | -4.4% | -0.5% | +3.5% | +42.6% | — |
| Aug 8, 2025 | AMC | -1.82 | -1.71 | +6.0% | 7.38 | -0.8% | -2.4% | +3.3% | +5.8% | +2.5% | +3.1% | — |
| May 14, 2025 | AMC | -2.03 | -1.41 | +30.5% | 3.27 | -0.3% | -1.5% | +14.0% | -0.8% | +8.5% | -4.6% | — |
| Mar 31, 2025 | AMC | -2.28 | -1.74 | +23.7% | 5.73 | +1.9% | +0.0% | -16.8% | -2.9% | -8.4% | -11.8% | — |
| Nov 12, 2024 | AMC | -2.43 | -1.93 | +20.6% | 7.09 | -1.0% | -2.0% | -2.7% | -0.9% | -1.5% | -2.0% | — |
| Aug 6, 2024 | AMC | -4.41 | -3.16 | +28.3% | 6.19 | -1.3% | -0.8% | -6.4% | +1.7% | +1.0% | +1.4% | — |
| May 14, 2024 | AMC | -2.89 | -4.20 | -45.3% | 6.87 | -2.3% | -1.6% | -0.4% | -2.7% | +1.2% | -0.8% | — |
| Mar 29, 2024 | AMC | -3.62 | -3.18 | +12.2% | — | — | — | — | — | — | — | — |
| Nov 13, 2023 | AMC | -2.15 | -3.41 | -58.6% | 5.53 | +0.1% | -6.0% | +1.3% | +0.9% | +2.4% | +9.4% | — |
| Aug 4, 2023 | AMC | -3.19 | -4.36 | -36.7% | 14.12 | -0.8% | -5.0% | -0.5% | -1.5% | +4.1% | -1.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 29 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $19.05 | $1.47 | -92.3% | -89.2% | -25.4% | -11.1% | +13.2% | +0.0% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.32 | $19.02 | +3.8% | -4.6% | +0.4% | +11.9% | -5.5% | -8.9% |
| Sep 11 | Oppenheimer | Maintains | Outperform → Outperform | — | $15.27 | $15.72 | +2.9% | +11.3% | +9.5% | +3.4% | -4.8% | -4.6% |
| May 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.09 | $4.08 | -0.2% | -1.2% | +0.5% | -6.4% | +1.1% | -3.1% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.63 | $4.63 | +0.0% | -8.4% | -11.8% | -6.4% | +10.0% | -11.2% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.44 | $7.40 | -0.5% | +4.3% | +8.0% | -13.8% | -6.2% | +1.0% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.76 | $6.66 | -1.5% | -0.9% | -1.5% | -2.0% | -0.6% | +1.9% |
| Aug 19 | Oppenheimer | Maintains | Outperform → Outperform | — | $6.11 | $6.11 | +0.0% | +2.8% | -1.0% | -3.4% | -0.2% | +0.2% |
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.73 | $6.66 | -1.0% | -2.7% | +1.2% | -0.8% | -1.1% | -0.2% |
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.99 | $8.00 | +0.1% | +0.0% | -2.6% | -0.4% | -1.9% | +0.3% |
| Apr 1 | Oppenheimer | Maintains | Outperform → Outperform | — | $7.97 | $8.00 | +0.4% | +0.3% | +0.0% | -2.6% | -0.4% | -1.9% |
| Nov 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.32 | $5.55 | +4.3% | +2.4% | +9.4% | +1.0% | +3.4% | -0.2% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.69 | $13.91 | +1.6% | -1.7% | +1.0% | +0.8% | +0.1% | -1.2% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.41 | $15.70 | +1.9% | -0.4% | +15.6% | -8.2% | +2.4% | -0.5% |
| May 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.77 | $15.37 | -2.5% | -2.6% | -1.1% | +2.0% | -1.8% | +0.7% |
| Apr 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.04 | $17.76 | +4.2% | +2.5% | +2.1% | -6.8% | +0.2% | -5.2% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.57 | $15.95 | +2.4% | -3.0% | +4.0% | -5.7% | -1.5% | +3.1% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.75 | $21.20 | +26.6% | +33.4% | -15.8% | +15.9% | -13.8% | +0.2% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.80 | $16.50 | -1.8% | -1.2% | +0.0% | -0.3% | -2.1% | -4.3% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.30 | $27.80 | -8.3% | -21.6% | -15.8% | -13.2% | +1.2% | -0.9% |
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.10 | $38.00 | +2.4% | -0.3% | -5.5% | -2.4% | -5.1% | -6.3% |
| Mar 30 | Northland Capital Markets | Maintains | Outperform → Outperform | — | $75.00 | $72.00 | -4.0% | -2.7% | -5.5% | -5.1% | -2.3% | -4.7% |
| Mar 30 | JP Morgan | Downgrade | Neutral → Underweight | — | $75.00 | $72.00 | -4.0% | -2.7% | -5.5% | -5.1% | -2.3% | -4.7% |
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $75.00 | $72.00 | -4.0% | -2.7% | -5.5% | -5.1% | -2.3% | -4.7% |
| Aug 6 | JP Morgan | Downgrade | Overweight → Neutral | — | $159.00 | $151.75 | -4.6% | -1.3% | +10.2% | -7.8% | -0.3% | -1.9% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $159.00 | $151.75 | -4.6% | -1.3% | +10.2% | -7.8% | -0.3% | -1.9% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $297.50 | $297.00 | -0.2% | -11.4% | +3.0% | -3.1% | +4.8% | -0.7% |
| Sep 14 | Jefferies | Downgrade | Buy → Hold | — | $438.50 | $421.50 | -3.9% | -8.9% | +0.8% | +7.0% | +1.5% | +12.5% |
| Jul 23 | Northland Capital Markets | Maintains | Outperform → Outperform | — | $512.00 | $524.50 | +2.4% | +0.1% | -5.2% | -4.9% | +0.0% | -7.5% |
| Jun 1 | Oppenheimer | Maintains | Outperform → Outperform | — | $615.50 | $616.50 | +0.2% | +8.9% | +2.9% | -0.9% | -2.3% | +1.7% |
| May 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $634.50 | $631.50 | -0.5% | -2.9% | -0.6% | +0.5% | +8.9% | +2.9% |
| May 27 | JP Morgan | Maintains | Overweight → Overweight | — | $634.50 | $631.50 | -0.5% | -2.9% | -0.6% | +0.5% | +8.9% | +2.9% |
| May 8 | H.C. Wainwright | Maintains | Buy → Buy | — | $592.50 | $609.00 | +2.8% | -4.6% | +5.6% | +0.2% | +0.5% | -2.1% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $337.00 | $341.00 | +1.2% | +2.4% | -0.1% | +1.6% | +5.6% | +1.5% |
| Mar 10 | Wedbush | Maintains | Outperform → Outperform | — | $396.50 | $420.00 | +5.9% | -0.5% | -3.3% | -6.8% | -8.9% | -5.4% |
| Mar 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $396.50 | $420.00 | +5.9% | -0.5% | -3.3% | -6.8% | -8.9% | -5.4% |
| Dec 17 | Bank of America | Downgrade | Buy → Neutral | — | $235.00 | $220.50 | -6.2% | -13.2% | -2.8% | +1.9% | -0.5% | -1.7% |
| Nov 8 | JP Morgan | Maintains | Overweight → Overweight | — | $185.50 | $178.00 | -4.0% | +10.8% | -3.9% | -7.1% | +1.1% | -2.7% |
| Aug 7 | H.C. Wainwright | Maintains | Buy → Buy | — | $219.00 | $218.00 | -0.5% | +16.7% | -10.0% | +9.1% | -3.8% | -4.8% |
| Apr 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $372.00 | $381.00 | +2.4% | +1.3% | +0.8% | +4.2% | -2.0% | -4.5% |
| Mar 14 | Jefferies | Maintains | Buy → Buy | — | $402.50 | $416.00 | +3.4% | +4.5% | +3.1% | -1.5% | -0.6% | -3.2% |
| Nov 14 | JP Morgan | Maintains | Overweight → Overweight | — | $328.00 | $332.00 | +1.2% | -3.4% | +4.3% | +0.2% | -5.3% | -2.7% |
| Aug 24 | H.C. Wainwright | Maintains | Buy → Buy | — | $625.50 | $645.00 | +3.1% | +2.6% | +0.7% | -0.2% | +0.2% | +3.6% |
| Jul 23 | H.C. Wainwright | Maintains | Buy → Buy | — | $615.50 | $640.00 | +4.0% | +2.6% | +1.3% | +1.5% | -4.1% | -1.8% |
| Jan 25 | Wells Fargo | Maintains | Outperform → Outperform | — | $746.00 | $772.50 | +3.6% | +0.1% | +0.8% | +0.4% | -1.4% | +2.1% |
| Aug 14 | Wedbush | Maintains | Outperform → Outperform | — | $983.00 | $1073.00 | +9.2% | +9.3% | +2.4% | +1.6% | -2.8% | -1.7% |
| Aug 14 | JP Morgan | Maintains | Overweight → Overweight | — | $983.00 | $1073.00 | +9.2% | +9.3% | +2.4% | +1.6% | -2.8% | -1.7% |
| Aug 14 | Wells Fargo | Maintains | Outperform → Outperform | — | $983.00 | $1073.00 | +9.2% | +9.3% | +2.4% | +1.6% | -2.8% | -1.7% |
No insider trades available.
8-K · 8.01
!! High
KALA BIO, Inc. -- 8-K 8.01: Material Event / Announcement
Kala Biopharmaceuticals announced a reverse stock split, a financial restructuring that consolidates shares to potentially improve stock price and market perception.
May 7
NT 10-K
!!! Very High
Unknown — Late Annual Report — Distress Signal
Kala Pharmaceuticals' late 10-K filing signals potential financial distress or operational challenges, creating uncertainty about the company's viability and making the stock riskier for investors seeking stable holdings.
Mar 31
8-K · 1.01
!! High
KALA BIO, Inc. -- 8-K 1.01: Material Agreement
Kala Biopharmaceuticals secured an exclusive platform development and licensing agreement, potentially expanding its pipeline and revenue opportunities through partnerships or technology collaborations.
Mar 4
8-K · 5.02
!!! Very High
KALA BIO, Inc. -- 8-K 5.02: Executive Change
David Lazar's resignation as a director at Kala Biopharmaceuticals reduces board oversight capacity, potentially signaling internal concerns or strategic disagreements that investors should monitor closely.
Feb 20
8-K · 5.02
!!! Very High
KALA BIO, Inc. -- 8-K 5.02: Executive Change
Avi Minkowitz was appointed Vice President at Kala Bio, signaling internal leadership reorganization that may indicate strategic shifts in company operations.
Feb 5
8-K · 5.02
!!! Very High
KALA BIO, Inc. -- 8-K 5.02: Executive Change
Kala Bio's executive leadership transition, detailed in this 8-K filing, may impact operational continuity and investor confidence depending on the nature and scope of the management changes announced.
Feb 2
Data updated apr 25, 2026 5:10pm
· Source: massive.com